期刊
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
卷 143, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ejps.2019.105096
关键词
GMP; ATMP; Semliki Forest Virus; recombinant viral particles; vaccine; Human Papilloma Virus
资金
- Dutch Cancer Society: National Cancer Control Programme (NPK) [RUG 2009-4579, RUG 2011-5156]
- European Fund for Regional Development (EFRO) [068/073]
Therapeutic vaccination is being explored as a treatment strategy for the treatment of patients with primary or metastatic tumours. We developed a vaccine targeted to Human papillomavirus (HPV)-induced tumours based on recombinant Semliki Forest virus (rSFV) encoding a fusion protein of the E6 and E7 proteins of HPV type 16. To enable a phase I clinical trial with this vaccine, Vvax001, a Good Manufacturing Practice (GMP)-compliant manufacturing process was set up and clinical material was produced. Upstream production of the clinical material resulted in viral titers from 2.4 x 10(7) to 1.3 x 10(9) infectious particles/ mL in the harvest. The total volume of 6.0 liter crude virus was purified in 13 consecutive downstream purification runs. The mean titer after purification was 4.0 x 10(8) infectious particles/mL and the mean recovery was 19%. Finally, clinical material was filled at a target concentration of 1.25 x 10(8) infectious particles/mL. Release testing included tests for viral titer and virus identity, biological activity, sterility, bacterial endotoxins, adventitious viruses and absence of replication competent virus. The product complied with all specifications and was released for use as an investigational medicinal product. This is the first GMP production process developed for a SFV-based therapeutic vaccine. The vaccine, Vvax001 is targeted to HPV and has shown promising results in preclinical studies. The GMP-produced Vvax001 material met the quality criteria and was of sufficient quantity to enable assessment of its immunogenicity, safety and efficacy in a clinical setting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据